Business
Neurotrope Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute (NCI) Trial for Childhood Leukemia
- Neurotrope and Metuchen continue to move toward closing the previously announced merger -Two separate publicly listed companies result: men's health
About this update from Nexttrip, Inc.
[{"type":"text","content":"- Neurotrope and Metuchen continue to move toward closing the previously announced merger\n -Two separate publicly listed companies result: men's health company, Petros Pharmaceuticals, Inc. and Bryostatin-1 neurological disease company, Neurotrope Bioscience, Inc.\n\n\nNEW YORK, June 10, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) (\"Neurotrope\" or the \"Company\") today announced its entry into a strategic agreement with BryoLogyx Inc., www.BryoLogyx.com, for the supply of synthetic, GMP-certified Bryostatin-1, manufactured by Albany Molecular Research, Inc. (\"AMRI\"), a leading global CDMO provider of advanced drug development and manufacturing solutions. Neurotrope expects to use the synthetic Bryostatin-1 in its clinical development initiatives aimed at advancing its lead product candidate for the treatment of Alzheimer's disease (\"AD\") and other neurodegenerative diseases and, ultimately, as a source for potential commercial drug supply if regulatory approval is received. \n\"This strategic partnership with BryoLogyx brings to Neurotrope the first fully synthetic, scalable source of Bryostatin-1, providing a clinical supply for the Company's planned Phase 3 study and a manufacturing alternative that delivers a dramatically superior cost of goods,\" stated Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope. \"Having better ongoing access to Bryostatin-1 drug supply is expected to have a positive impact on our future development efforts and, ultimately, our potential commercialization efforts if regulatory approval is received. Neurotrope has an exclusive license agreement with Stanford University for the use of this synthetic Bryostatin-1 in the treatment of all neurological disorders. In addition, BryoLogyx's innovation-driven work utilizing bryostatins for use in cancer immunotherapy make them an ideal partner to continue advancement of the CD22+ B-cell acute lymphoblastic leukemia (\"ALL\") development program, where they have the expertise and resources to realize its full potential.\"\nUnder the terms of the agreement, BryoLogyx will supply Neurotrope with specified amounts of synthetic, GMP-grade Bryostatin-1., manufactured by AMRI Group. BryoLogyx will pay a fee on gross revenues generated by the commercial sale of Bryostatin-1 product sold by BryoLogyx for the treatment of ALL. In ex...